The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Hypersensitivity reactions from taxol.
R B Weiss; R C Donehower; P H Wiernik; T Ohnuma; R J Gralla; D L Trump; J R Baker; D A Van Echo; D D Von Hoff; B Leyland-Jones (Profiled Author: Ross Donehower)
Department of Medicine, Walter Reed Army Medical Center, Washington, DC 20307.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(7):1263-8.
Taxol is an antitumor agent in clinical trial that has been shown to have activity against advanced ovarian carcinoma and melanoma. Hypersensitivity reactions (HSRs) have been one of the toxicities observed with administration of this drug. Of 301 patients treated, 32 patients have had definite (27 patients) or possible (five patients) hypersensitivity reactions to taxol. All but one patient had the reaction from the first or second exposure to this agent. Reactions occurred at a variety of doses and were characterized most frequently by dyspnea, hypotension, bronchospasm, urticaria, and erythematous rashes. Thirteen (41%) patients had received premedication designed to prevent such toxicity; nevertheless, they sustained HSRs. Prolonging the drug infusion appears to have somewhat reduced, but not obviated, the risk of HSRs. The cause (taxol itself or its excipient Cremophor EL; Badische Anilin und Soda-Fabrik AG [BASF], Ludwigshafen, Federal Republic of Germany) and the mechanism of these reactions to taxol are unknown. We provide guidelines to prevent or minimize such toxicity and treat reactions if they still occur.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
R C Donehower; E K Rowinsky; L B Grochow; S M Longnecker; D S EttingerCancer treatment reports 1987;71(12):1171-7.
D M Peereboom; R C Donehower; E A Eisenhauer; W P McGuire; N Onetto; J L Hubbard; M Piccart; L Gianni; E K RowinskyJournal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):885-90.
W J Slichenmyer; R C Donehower; T L Chen; M K Bowling; W P McGuire; E K RowinskyCancer chemotherapy and pharmacology 1995;36(3):227-32.
Appears in this Publication
Author of this Publication